Skip to content

In Australia, this personalised treatment has already shown powerful results in some types of blood cancers, including leukaemia and lymphoma.

But researchers at The Baker Institute want to take it further.

At the moment, CAR T therapy is not widely used for solid cancers like melanoma, and one of the big reasons is that the treatment doesn’t work as well in the complex environment of solid tumours. These complex environment can make it harder for the reprogrammed cells to survive and do their job.

Our team is working on new ways to improve how CAR T cells are made, with the goal of helping them perform better—not just in blood cancers, but potentially in solid cancers too. This could one day open up treatment options for more people and make CAR T therapy more effective and more accessible.

But we can’t do it alone.

We are seeking input from people with lived experience, clinical or scientific expertise, or an interest in cancer care to ensure that the future development of CAR T cell therapy is informed, ethical, and aligned with community needs. By this, we mean not only healthcare professionals and researchers, but also people affected by cancer—including anyone who has been diagnosed, as well as those who have supported someone with cancer, such as a family member, friend, or carer. Your insights will help guide how this therapy is developed, delivered, and communicated in the future.


Take the short survey

This Baker Institute survey takes around 5 minutes.

Have a conversation with researchers at the Baker Institute

if you’re open to sharing more, we’d love to speak with you via phone, video call, or in person.

Dr Pooranee Morgan is a postdoctoral researcher in the Haematopoiesis and Leukocyte Biology laboratory at the Baker Heart and Diabetes Institute Melbourne, Victoria. Pooranee’s current focus is identifying and developing potential therapeutic applications to alter immune cellular sensitivity to ferroptosis, a form of cell death mechanism.

Read more here.

Early detection with 3d imaging

Early detection with 3d imaging

The recent Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) Community &a…

Melanoma risk

Melanoma personal risk

Melanoma: would you want to know your personal risk? If you could combine all your risk factors—your…

MSCAN & Melbourne Renegades Media Release

MSCAN & Melbourne Renegades Media Release

From Sixes to Skin Checks: Melbourne Renegades team up to drive skin cancer awareness message at the…